Personalized ECT for better depression treatment outcomes
Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial
This study is testing if adjusting the strength of ECT treatment for depression can help older adults feel better and think more clearly compared to using a standard strength.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of New Mexico Academic / other |
| Locations | 1 site (Albuquerque, New Mexico) |
| Trial ID | NCT05699226 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effects of individualized amplitude ECT versus fixed 800 mA ECT on depression and cognitive outcomes in older adults. Participants will undergo baseline assessments before receiving ECT treatments, with evaluations conducted at multiple time points to measure antidepressant response and cognitive function. The study hypothesizes that personalized amplitude adjustments will lead to improved treatment efficacy and reduced cognitive impairment compared to traditional fixed dosing. A total of 50 subjects will be enrolled, with assessments focusing on neuroplasticity and clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates are older adults diagnosed with major depressive disorder or bipolar II who are clinically indicated for ECT.
Not a fit: Patients with defined neurological disorders, other psychiatric conditions, or contraindications to MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer ECT treatments for older patients with depression.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in optimizing ECT dosing based on individual patient characteristics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of major depressive disorder or bipolar II * Clinical indications for ECT with right unilateral electrode placement Exclusion Criteria: * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease) * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder) * Current drug or alcohol use disorder (except for nicotine) * Contraindications to MRI.
Where this trial is running
Albuquerque, New Mexico
- University of New Mexico Health Science Center — Albuquerque, New Mexico, United States (Recruiting)
Study contacts
- Principal investigator: Chris Abbott, MD — University of New Mexico
- Study coordinator: Chris Abbott, MD
- Email: cabbott@salud.unm.edu
- Phone: 5052720406
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.